PGI5 COST-EFFECTIVENESS OF NATALIZUMAB IN CROHN'S DISEASE PATIENTS WHO HAVE FAILED ANTI-TNF ALPHA THERAPY  by Panjabi, S et al.
inﬂiximab. METHODS: Thirty one gastroenterologists from
southeast Brazil prospectively evaluated all their Crohn’s disease
patients during two months. They used a structured question-
naire speciﬁcally developed to evaluate resource use by patients
with Crohn’s disease. RESULTS: A total of 118 patients with
moderate and severe disease were evaluated during 2 months.
The patients average age was 30 years and the mean body weight
was 62 kg. Fourteen patients were using inﬂiximab. The com-
parison among inﬂiximab patients and standard care patients
showed that 60.6% of the standard care patients needed hospi-
talization and only 21.4% of the inﬂiximab patients needed
hospitalization (p = 0.005). The main reason for hospitalization
among the standard care patients was due to anal ﬁstula, and
among the inﬂiximab patients, was due to anemia/hemorrhage.
CONCLUSION: The use of inﬂiximab in the management of
moderate and severe Crohn’s disease can be contributive to
reduction of the need of hospitalization among these patients.
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OBJECTIVE: To compare the cost-effectiveness (CE) of natali-
zumab (NAT) to FDA-approved tumor-necrosis factor alpha
inhibitors (anti-TNFa) in Crohn’s disease (CD). METHODS:
Decision analysis was used to model treatment for patients with
moderate-to-severe CD (Crohn’s Disease Activity Index scores
220 and <450). Patients are assumed to have failed treat-
ment with corticosteroids, immunomodulators, and anti-TNFa
therapy. The model includes an induction phase followed by a
two year maintenance phase comparing NAT 300 mg, inﬂiximab
(INF) 5 mg/kg or 10 mg/kg, and adalimumab (ADA) 40 mg
every other week or weekly. At the end of induction and each of
the four six-month maintenance cycles, patients enter one of
three efﬁcacy states (remission, response, nonresponse) that are
estimated from phase III clinical studies and NAT clinical data.
Total costs associated with each comparator agent are composed
of pharmacy and medical costs derived from published price lists
and analyses of CD claims from a database assembled by Health
Benchmarks International. Drug costs for INF and ADA were
weighted by dose based upon the distribution observed in pub-
lished phase IV studies. RESULTS: Over the two year mainte-
nance period, NAT patients on average were estimated to be in
remission for 0.41 years versus 0.22 and 0.26 for those receiving
INF and ADA, respectively. Average total costs over induction
and maintenance were predicted to be $62,377 (NAT), $55,195
(INF), and $56,654 (ADA). NAT was associated with 13% and
10% increases in total cost compared to INF and ADA, but
resulted in 86% and 57% increases in remission duration over
the comparators, respectively. The CE ratio for NAT relative to
ADA and INF remained insensitive to increases in NAT-related
costs (up to $36,000) or decreases in NAT efﬁcacy (up to -25%).
CONCLUSION: This model, based on estimates from the avail-
able published literature, projected NAT to be the most cost-
effective treatment alternative for patients who had failed prior
anti-TNFa therapy.
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OBJECTIVE: Recombinant factor VIIa, an expensive coagula-
tion factor, was previously utilized pre-operatively at UC San
Diego Medical Center (UCSDMC) to reduce blood loss during
Orthotopic Liver Transplant (OLT). Recent large randomized,
controlled clinical trials have demonstrated a lack of efﬁcacy and
a potential risk of thromboembolic complications. As a result,
use of recombinant factor VIIa for bleeding prophylaxis in OLT
was discouraged due to compromised cost-effectiveness. This
change in practice warranted validation through pharmacoeco-
nomic outcomes research. METHODS: A single-center, retro-
spective review was performed to determine if the change in
UCSDMC OLT guidelines resulted in negative outcomes. The
primary outcome measure was the volume of blood products
required during OLT. Secondary outcomes included total cost of
care, operating room time, LOS, and thromboembolic events.
RESULTS: 119 liver transplant recipients were included in the
analysis. There was no signiﬁcant difference in the primary
outcome of blood product requirement. Patients receiving factor
VIIa failed to demonstrate any statistically signiﬁcant reduction
in need for PRBC 13.8 vs 13.4 units (p = 0.9), FFP 11.3 vs 15.6
(p = 0.2), or PLT 4 vs 6.6 (p = 0.08) when compared to controls.
The secondary outcome measurements also failed to reach sta-
tistical signiﬁcance, including LOS 23 vs 15 days (p = 0.17),
blood costs (p = 0.92), surgical costs (p = 0.69), and total cost of
care (p = 0.15). Two patients developed hepatic artery thrombo-
sis in the treatment group compared to one patient in the control
group. As measured by the Scientiﬁc Registry of Transplant
Recipients (SRTR), no signiﬁcant changes in liver transplant
patient or graft survival were noted. An 83% reduction average
recombinant factor VIIa use during OLT has been demonstrated,
resulting in annual savings of $170 K. CONCLUSION: Recom-
binant factor VIIa use for reduction of blood product require-
ments in OLT has not been demonstrated to be cost-effective and
may be associated with a risk of thromboembolic events.
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OBJECTIVE: Associated with no screening, H. pylori serology
screening, and the 13C-Urea breath test (UBT) for gastric cancer
in Chinese. METHODS: A Markov model simulation was
carried out in Singaporean Chinese at age of 40 years
(n = 478,500) from the perspective of public health care provid-
ers. The main outcome measures were costs, number of gastric
cancer cases prevented, life years saved, quality-adjusted life-
years (QALYs) gained from the screening age to death, and
incremental cost-effectiveness ratios (ICERs), which were com-
pared among the three strategies. The uncertainty surrounding
ICERs was addressed by scenario analyses and probabilistic sen-
sitivity analysis using Monte Carlo simulation. RESULTS: The
ICER of serology screening versus no screening was $25,881 per
QALY gained (95% conﬁdence interval (95% CI): $5700 to
$120,000). The ICER of UBT versus no screening was $53,602
per QALY gained (95% CI: $16,000 to $230,000). ICER of UBT
versus serology screening was $470,000 per QALY gained, for
which almost all random samples of the ICERs distributed above
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